U.S. Markets closed

Enzo Biochem, Inc. (ENZ)

NYSE - Nasdaq Real Time Price. Currency in USD
Add to watchlist
10.67+0.22 (+2.11%)
At close: 3:59PM EDT

10.66 0.00 (0.00%)
After hours: 4:40PM EDT

People also watch

Enzo Biochem, Inc.

527 Madison Avenue
New York, NY 10022
United States

IndustryMedical Laboratories & Research
Full Time Employees446

Key Executives

Dr. Elazar Rabbani Ph.D.Co-Founder, Chairman, Chief Exec. Officer and Sec.1.32MN/A74
Mr. Barry W. WeinerCo-Founder, Pres, Chief Financial Officer, Principal Accounting Officer, Treasurer and Director1.08MN/A67
Mr. James Michael O’BrienExec. VP of Fin.409.66kN/A51
Dr. Dieter Schapfel M.D.Chief Medical Director of Enzo Clinical Labs352.03kN/A54
Mr. Bruce A. DeyVP of Sales & Marketing - Enzo Clinical Labs507.01kN/A59
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Enzo Biochem, Inc., an integrated life science and biotechnology company, engages in the research, development, manufacture, and marketing of diagnostic and research products based on genetic engineering, biotechnology, and molecular biology. The company operates in three segments: Clinical Labs, Life Sciences, and Therapeutics. The Clinical Labs segment provides routine and esoteric clinical laboratory tests or procedures used in general patient care by physicians to establish or support a diagnosis, monitor treatment or medication levels, and search for an otherwise undiagnosed condition. This segment operates a full-service clinical laboratory in Farmingdale, New York; a network of approximately 30 patient service centers in New York and New Jersey; and a free standing ‘STAT’ or rapid response laboratory in New York City, as well as a full-service phlebotomy department. The Life Sciences segment manufactures, develops, and markets products and tools to life sciences, drug development, and clinical research customers. It offers proteins, antibodies, peptides, small molecules, labeling probes, dyes, and kits, which provide tools for target identification/validation, content analysis, gene expression analysis, nucleic acid detection, protein biochemistry and detection, and cellular analysis to life science researchers. This segment provides its products to scientific experts in the fields of cancer, cardiovascular disease, neurological disorders, diabetes and obesity, endocrine disorders, infectious and autoimmune disease, hepatotoxicity, and renal injury. The Therapeutics segment is involved in the research and development of therapeutic drug candidates in the areas of gastrointestinal, infectious, ophthalmic, and metabolic diseases. The company markets its products and services through its direct sales force and a network of distributors in the United States and internationally. Enzo Biochem, Inc. was founded in 1976 and is headquartered in New York, New York.

Corporate Governance

Enzo Biochem, Inc.’s ISS Governance QualityScore as of September 1, 2017 is 10. The pillar scores are Audit: 2; Board: 9; Shareholder Rights: 10; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.